News Finding: "The CHI3L1 is doing exactly what it is supposed to do -- it is designed to shut off cell death and decrease injury," said Dr. Jack A. Elias, a co-senior author of the study and dean of medicine and biological sciences at Brown University.
Paper Finding: these observations raise the possibility that CHI3L1 might also be a useful therapeutic that could control tissue injury.
News Context: In IPF, 70 percent of patients die within five years. "The CHI3L1 is doing exactly what it is supposed to do -- it is designed to shut off cell death and decrease injury," said Dr. Jack A. Elias, a co-senior author of the study and dean of medicine and biological sciences at Brown University. "But at the same time it is decreasing cell death it is driving the fibrosis.
Paper Context: n = 6 mice per group. these observations raise the possibility that CHI3L1 might also be a useful therapeutic that could control tissue injury. Its utility in this setting would be further enhanced if subsequent studies define ways to separate the antiapoptotic and fibroproliferative effects of this CLP, allowing the protective effects of the former to manifest without engendering excess scarring.